Aptar Pharma
Aptar Pharma, a segment of AptarGroup (NYSE: ATR), is a global supplier of proprietary drug delivery systems — nasal, injectable, and inhalation — plus pharmaceutical services and digital health solutions serving pharmaceutical developers, healthcare providers, and emergency medicine applications across 19+ countries.
- Company typePublic
- Founded1942
- HeadquartersCrystal Lake, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aptar Pharma does
Aptar Pharma is a business segment of AptarGroup, Inc. (NYSE: ATR), a publicly traded global supplier of drug delivery systems, components, and pharmaceutical services founded in 1942 and headquartered in Crystal Lake, Illinois, with European operations anchored in Rueil-Malmaison, France. The segment designs and manufactures proprietary delivery platforms across nasal (Unidose System, Freepod bio-based pumps, SipNose intranasal technology), injectable (PremiumCoat elastomeric plungers, Micro+ Futurity recyclable airless systems, USP <382> testing framework, aseptic RTP bags), and inhalation (Orbital DPI, Kolibri Mesh Nebuliser with guided breathing) routes, alongside HeroTracker Sense digital respiratory monitoring and digital companion solutions for wearable injectors such as Enable Injections' enFuse. Manufacturing runs across 19+ countries with 3+ billion valves produced annually and ISCC PLUS-certified sites in Switzerland and Germany supporting bio-based and recycled material production.
The company operates a B2B enterprise model serving pharmaceutical developers (primary), healthcare providers, and emergency-medicine applications including naloxone, epinephrine, and glucagon delivery. Revenue is generated through hardware sales of devices and components, professional services spanning formulation development (via subsidiary Nanopharm) and regulatory support, and recurring/subscription revenue from digital health solutions under the Aptar Digital Health subsidiary. Go-to-market relies on enterprise field sales, inside sales for quoting and account management, strategic co-development partnerships (Stallergenes Greer, Enable Injections, COVIRIX Medical, PULMOTREE, LoValTech), and channel distribution where appropriate. Pricing is non-public, quote-based enterprise contracting.
Aptar Pharma combines device expertise with formulation services (Nanopharm GMP-certified), regulatory testing support, and digital adherence platforms into an integrated 3D value proposition most explicitly positioned for GLP-1 drug delivery via autoinjectors, pen injectors, and vial systems. Recent strategic activity includes the SipNose technology acquisition (Oct 2024) extending into nose-to-brain CNS therapeutics, a new French factory announced for GLP-1 capacity (Jan 2026), and the Freepod bio-based nasal pump launch. The company is led by President and CEO Stephan B. Tanda (since 2017) and employs 10,000+ people globally, with TIME Top 100 America's Best Companies (2026, ranked 83), EcoVadis Gold, and consecutive CDP Supplier Engagement Leader recognition signaling sustained execution on innovation and ESG dimensions.
Aptar Pharma firmographics
Firmographics- Name
- Aptar Pharma
- Legal name
- APTARGROUP, INC.
- Website
- https://aptar.com
- Company type
- Public
- Founded year
- 1942
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Aptar Pharma, a segment of AptarGroup (NYSE: ATR), is a global supplier of proprietary drug delivery systems — nasal, injectable, and inhalation — plus pharmaceutical services and digital health solutions serving pharmaceutical developers, healthcare providers, and emergency medicine applications across 19+ countries.
- Ownership category
- akta.pro rank
Aptar Pharma industry classification
Industry- Product category
- Pharmaceutical Drug Delivery Systems
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)
- akta.pro secondary industries
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK), Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Aptar Pharma is headquartered
LocationHeadquarters
- HQ city
- Crystal Lake
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Aptar Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Delivery Devices and Components: Sale of proprietary drug delivery systems including nasal spray pumps, Unidose Systems, inhalers, and injectable components to pharmaceutical companies
- Pharma Services: Integrated pharmaceutical services including drug formulation, regulatory support, and technical development throughout the product lifecycle
- Digital Health Solutions: Digital patient solutions and connected device technologies that integrate with drug delivery systems for enhanced patient outcomes
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Aptar Pharma product offering
Product offeringCore offering
Aptar Pharma designs, manufactures, and sells proprietary drug delivery systems and components—including nasal spray pumps (Unidose System, Freepod), injectable components (elastomeric plungers, vial and syringe components), inhalation devices (dry powder inhalers, mesh nebulizers), and ophthalmic dispensers—to pharmaceutical companies. The company also provides integrated pharma services spanning formulation development, regulatory support, and digital health solutions such as connected respiratory monitoring.
Product overview
Aptar Pharma is a drug delivery solutions company offering a comprehensive portfolio of pharmaceutical delivery systems and services. The core offerings include the Unidose System (UDS) for nasal emergency therapies, Freepod bio-based nasal spray pumps, Ophthalmic Squeeze Dispensers for preservative-free eye care, and Orbital DPI technology for dry powder inhalation. The company provides integrated injectable delivery frameworks addressing USP <382> requirements, as well as aseptic transfer solutions including Rapid Transfer Port (RTP) bags for pharmaceutical manufacturing. Digital health offerings include HeroTracker Sense for respiratory medicine and digital companion solutions for wearable injectors. Supporting services include GLP-1 drug delivery solutions, FDA-funded research on inhaler propellants, and acquired technologies such as SipNose nasal delivery systems. The portfolio is complemented by manufacturing capabilities across multiple global sites including Switzerland, Germany, Brazil, and France, with ISCC PLUS certifications enabling sustainable and recycled material production.
Differentiator
Problem solved
Functional benefit
Brands
- SipNose: Nasal delivery technology assets acquired for nose-to-brain and CNS therapeutics delivery.
- Gaia
- SimpliCycle
- SimpliSqueeze
- Swimming Silicone
- Freepod
- Unidose System (UDS)
- Orbital DPI
- Kolibri
- PremiumCoat
- HeroTracker Sense
Products and services
- Unidose System (UDS) Nasal drug delivery platform with over 30 years of operational history, FDA and EMA regulatory approval, and hundreds of millions of units delivered globally. Positioned for emergency therapies including opioid overdose (naloxone), anaphylaxis (epinephrine), and hypoglycemia (glucagon), offering customizable formulations for pharmaceutical developers.
- Freepod Bio-Based Nasal Spray Pump Nasal spray pump made with mass balance bio-based resins, containing 52% ISCC Plus certified bio-based feedstock. When combined with the bottle, achieves 60% circular material content. Manufactured at Aptar's ISCC PLUS certified site in Mezzovico, Switzerland, for pharmaceutical and consumer health customers.
- Ophthalmic Squeeze Dispenser
Quantifiable outcome
- Over 30 years of FDA and EMA regulatory approval track record for Unidose System
- +2 more outcomes
Companies that use Aptar Pharma
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles4 records
Aptar Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature10 records
Aptar Pharma partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, flagship and minor.
- Enable InjectionscoreStrategic partnership to deliver a digital companion solution for the enFuse wearable injector system, featuring treatment data recording, injection guidance, patient-reported outcomes, and symptom tracking.
- COVIRIX MedicalcoreTechnical collaboration to adapt Aptar's dry powder inhalation platform (Orbital DPI) for delivering COVIRIX Medical's broad-spectrum antiviral compounds against pandemic-potential respiratory viruses including COVID-19, influenza, and RSV.
- SipNose Nasal Delivery SystemscoreAcquisition of device technology assets from Israeli company SipNose to expand intranasal drug delivery capabilities, particularly for nose-to-brain and CNS therapeutics.
- LoValTechflagshipLoValTech and Aptar Pharma awarded France 2030 funding (8.4 million euros) for developing a nasal vaccine combined with a medical device to finalize a COVID-19 vaccine that prevents severe illness and transmission.
- Stallergenes GreercorePartnership to develop a connected drug delivery device for allergy immunotherapy treatments, combining Stallergenes' immunotherapy expertise with Aptar's delivery technology.
- NanopharmcoreFormulation development services partner for the COVIRIX Medical collaboration, providing expertise in dry powder formulation development for the inhalable antiviral project.
- PULMOTREEcoreCollaboration to develop Kolibri Mesh Nebuliser featuring guided inhalation technology with haptic feedback for precise biologic drug deposition in targeted lung regions.
- ClarinsflagshipLong-standing partnership developing custom reloadable airless packaging solution for Clarins Total Eye Lift eye cream using patented Gaïa technology, achieving 73% material reduction per reload.
- Cheer Pack North AmericacorePartnership providing SureSnap flow control valve and retaining ring for Cheer Pack N.A.'s SqueezeNSip spout, enabling leak-free dispensing for on-the-go beverages and food products.
- Ecological GroupminorPartnership with Brazilian waste management company to collect and recycle BOPP flexible plastic film materials into post-consumer recycled resin for manufacturing closures.
- PureCycle TechnologycorePreferred converting partner for Ultra-Pure Recycled PP (UPRP) applications, investigating incorporation of post-consumer recycled materials for circular economy contribution.
- EcoverminorPartnership launched first dispensing closure in Europe made from 50% post-consumer recycled resin for Ecover washing up liquid products (2019).
Scale indicators8 records
Recent moves6 records
Expansion highlights8 records
Aptar Pharma competitors and assessment
Company assessmentDirect peers
- Nemera: Nemera is a drug delivery device company offering nasal, ophthalmic, inhalation, and injectable delivery platforms. It is a directly comparable specialty drug delivery vendor competing for the same pharma partner programs across multiple delivery routes.
- Ypsomed Holding AG: Ypsomed specializes in injection systems for self-medication, including pen injectors and autoinjectors used in diabetes, GLP-1, and other injectable therapies. Direct overlap with Aptar's GLP-1 injection platform ambitions and pen injector components.
- West Pharmaceutical Services: West Pharmaceutical is the closest direct peer, providing elastomeric components, plungers, and containment systems for injectable drug delivery. Overlap with Aptar's PremiumCoat plunger line and pre-filled syringe platform is substantial, and both serve the same biologics and biosimilar pharma customers.
- Stevanato Group: Stevanato Group designs and manufactures drug containment solutions, syringes, and integrated device platforms for pharma. Like Aptar, it serves injectable and biologic delivery with proprietary components and offers both device engineering and manufacturing services.
- Gerresheimer AG: Gerresheimer is a global pharmaceutical packaging and drug delivery company producing glass primary packaging, plastic containers, and medical devices. It competes with Aptar on vial containment, syringes, and delivery systems for injectables and inhaled therapeutics.
- SCHOTT Pharma: SCHOTT Pharma manufactures primary packaging (vials, syringes, cartridges) and drug delivery solutions for the pharmaceutical industry. It is a direct comparable in containment and injectable delivery components, including services for high-value biologics.
Broad incumbents
- Amcor plc: Amcor is a global packaging giant that absorbed Berry Global in 2025, expanding its pharmaceutical and healthcare packaging footprint. It competes with Aptar in primary packaging, drug delivery components, and across the broader beauty/closures segments.
- Teleflex Medical: Teleflex is a diversified medical device manufacturer with pharmaceutical and respiratory delivery products. While broader, it overlaps with Aptar in specific delivery categories (e.g., respiratory drug delivery and specialty injectables).
- Becton, Dickinson and Company (BD): BD is a diversified medical device incumbent with major pharmaceutical systems and injectable delivery franchises (pre-filled syringes, autoinjectors, safety devices). It competes with Aptar across multiple delivery routes and is a scaled enterprise with broader portfolio reach.
Emerging players
- Catalent (Novo Holdings): Catalent is a major pharma services and drug delivery CDMO, providing softgel, inhalation, and injectable delivery solutions. Now under Novo Holdings, it competes with Aptar in formulation services and integrated drug-device development for partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Aptar Pharma social profiles
Digital presenceAptar Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aptar Pharma leadership team
Management profileNumber of profiles
Profiles13 records
Aptar Pharma subsidiaries and ownership
Company hierarchySubsidiaries5 records
Aptar Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aptar Pharma M&A and investment
M&A and investmentM&A3 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aptar Pharma
What does Aptar Pharma do?
Aptar Pharma designs, manufactures, and sells proprietary drug delivery systems and components—including nasal spray pumps (Unidose System, Freepod), injectable components (elastomeric plungers, vial and syringe components), inhalation devices (dry powder inhalers, mesh nebulizers), and ophthalmic dispensers—to pharmaceutical companies. The company also provides integrated pharma services spanning formulation development, regulatory support, and digital health solutions such as connected respiratory monitoring.
Is Aptar Pharma a public or private company?
Aptar Pharma is a public company. It is classified as public and is currently operating.
When was Aptar Pharma founded?
Aptar Pharma was founded in 1942. It employs 5,001 to 10,000 people.
Where is Aptar Pharma based?
Aptar Pharma is headquartered in Crystal Lake, United States, in the North America region.
How does Aptar Pharma make money?
Three revenue lines are on record. Drug Delivery Devices and Components are the primary driver. The others are pharma Services and digital Health Solutions.
Who are Aptar Pharma's main competitors?
Direct peers on record are Nemera, Ypsomed Holding AG, West Pharmaceutical Services, Stevanato Group, Gerresheimer AG and SCHOTT Pharma. Broad incumbents are Amcor plc, Teleflex Medical and Becton, Dickinson and Company (BD). Catalent (Novo Holdings) is listed as an emerging player.
Does Aptar Pharma have an API?
No public API is recorded for Aptar Pharma.
What industry is Aptar Pharma in?
Aptar Pharma's product category is Pharmaceutical Drug Delivery Systems. Its primary akta.pro industry code is HLAHAIAM, Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps), with a secondary code of HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 339112 and its SIC code is 3841.